Evidence that repression of NRF2 by KEAP1 is impaired in human cancer came initially from the laboratory of Shyam Biswal through the demonstration that the KEAP1 gene is subject to somatic mutations in some cell lines and clinical samples from patients with non-small cell lung cancer (NSCLC) [150]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.